Does Your Baby Really Need Two Weeks of Antibiotics?

What a Large New Review of Neonatal Infection Studies Says About Shortening Treatment Time

If your newborn was ever started on intravenous antibiotics in the hospital — for a suspected infection, a confirmed bloodstream infection, or a urinary tract infection — you may have been told treatment would last anywhere from a few days to three weeks, often without a clear explanation of why that particular number was chosen. A large new analysis pooling data from 26 studies and thousands of newborns has now tested, more rigorously than ever before, whether shorter courses of antibiotics work just as safely as the longer courses doctors have used for decades.[1] The short answer: for babies with a confirmed infection found in a blood test (a positive blood culture), shorter courses look reassuringly safe and get babies off intravenous lines sooner — but for babies treated for a suspected infection whose blood culture never actually grows anything, the evidence is more mixed, and doctors are being urged to proceed carefully rather than assume shorter is automatically fine.

Why This Question Has Taken So Long to Answer

Serious infection in the first weeks of life is one of the most common reasons newborns end up in intensive care, and it remains a leading cause of death for babies worldwide, which is exactly why doctors have long erred on the side of caution and treated for longer rather than shorter.[2] Decades ago, before modern intensive care, bacterial infections in newborns were often fatal, and the antibiotic durations doctors settled on — commonly two weeks for a confirmed bloodstream infection, about a week for a suspected-but-unconfirmed infection, three weeks for meningitis (an infection of the fluid around the brain and spinal cord) — were reasonable, cautious estimates rather than numbers proven by careful head-to-head testing. Those estimates then simply became tradition, repeated in textbook after textbook. The trouble is that giving antibiotics for longer than truly necessary is not free of cost: it can disturb the delicate community of bacteria developing in a baby's gut, increase the risk of yeast infections, and contribute to a problem doctors call antimicrobial resistance — germs evolving to survive the very drugs meant to kill them — a pattern now documented in newborn intensive care units around the world.[3] Research in older patients has directly linked unnecessarily long antibiotic courses to real side effects, including allergic reactions and other drug-related complications, reinforcing that "extra days just to be safe" are not automatically harmless.[4] One American hospital even showed that a structured program to trim unnecessary antibiotic use could cut exposure substantially with no evidence of harm to babies, hinting that "more" has never automatically meant "safer."[5]

What the Researchers Actually Did

A team of doctors and statisticians, led by researchers in India and writing in the medical journal eClinicalMedicine, combined the results of many smaller studies into seven separate analyses, each asking about a different kind of newborn infection: a confirmed bloodstream infection; using a blood marker of inflammation to decide when to stop antibiotics rather than picking a fixed number of days in advance; a suspected-but-unconfirmed bloodstream infection; a urinary tract infection; and meningitis (two further categories — infections of a brain-fluid shunt, and serious yeast infections in the bloodstream — turned out to have no usable studies at all, meaning those questions remain completely unanswered by research so far). Crucially, the team used a particularly strict and careful method: rather than just checking whether shorter treatment looked "about the same" as longer treatment, they decided in advance exactly how much worse a shorter course would be allowed to look — in terms of babies who died or whose infection came back — before they would call it acceptable. Only if the real results stayed safely within that pre-agreed boundary did they conclude the shorter course was truly "non-inferior," meaning not meaningfully worse.

What They Found

For babies with a confirmed bloodstream infection — one where the lab actually grew bacteria from a blood sample — pooling seven studies of 921 babies showed that a shorter course of about 7 to 10 days worked just as safely as the traditional 10 to 14 days, with no meaningful difference in deaths or infections coming back, and with the clear bonus of about five and a half fewer days on antibiotics and nearly four fewer days in the hospital. This finding drew heavily on a large study across multiple Indian newborn units led by Dr. Sourabh Dutta comparing seven days against fourteen, on an earlier study by Dr. Anurag Fursule and colleagues comparing ten days against fourteen for a specific group of bacteria, and on a similar ten-versus-fourteen-day study led by Dr. Kamirul Islam and colleagues.[6][7][8]

For babies whose treatment is guided by a blood marker instead of a fixed calendar date — most notably in a large study called the Neonatal Procalcitonin Intervention Study, or NeoPInS, run across 18 hospitals in the Netherlands, Switzerland, Canada, and the Czech Republic — stopping antibiotics as soon as a blood marker called procalcitonin returned to normal was just as safe as sticking to a fixed number of days, and shaved off a little extra treatment time.[9] This approach depends on a hospital having quick, reliable access to that blood test, so it is more likely to be offered in units set up to run and interpret the marker rapidly rather than being available everywhere yet.

The result that deserves the most caution involves babies treated for suspected infection whose blood culture never grew anything — in practice, one of the largest groups of newborns who receive antibiotics at all. Here, a very short course of just 3 to 4 days could not be shown to be as safe as the standard 5 to 7 days: the numbers left real uncertainty about whether deaths or infections returning might be somewhat more common with the shortest courses tested. This does not mean 3-to-4-day courses are unsafe — it means the research so far simply cannot rule out a meaningful difference, which is different from proving one is safe.

For urinary tract infections, the only available evidence came from six studies that simply observed what doctors already did, rather than randomly assigning babies to different treatment lengths — a much weaker kind of evidence — so the researchers concluded no firm answer could yet be given. For meningitis, only one small trial of 70 babies, led by Dr. N.B. Mathur, has ever directly compared antibiotic durations (10 versus 14 days), and it could not show that the shorter option was safely equivalent; a broader review of meningitis treatment in young infants likewise found too little trial evidence to recommend any specific duration with confidence.[10][11] That leaves current, longer-duration practice the more cautious choice for meningitis, for now.

What This Means for Your Baby's Care

If your baby has a bloodstream infection confirmed by a positive blood culture, is improving well clinically, and the treatment team suggests a shorter course of antibiotics — perhaps 7 to 10 days instead of two full weeks — this research offers real reassurance that shorter, closely monitored treatment is a reasonable, evidence-informed choice, not a corner being cut. If your baby is being treated for a suspected infection where cultures came back negative, it is entirely reasonable to ask your care team how they are deciding when to stop, since the science here is still evolving and most units continue to use longer courses in this situation out of caution. For urinary tract infections and meningitis, standard-length treatment remains the more evidence-supported path for now. In every case, the length of antibiotic treatment is a clinical decision your baby's doctors make based on how sick your baby was, how quickly they are improving, and what the cultures show — this research gives them better tools to make that decision, not a rigid new rulebook. It is always reasonable, and welcomed by most care teams, to ask directly: "Is this a confirmed infection or a suspected one, and how did you decide on this number of days?" A team confident in its reasoning should be able to answer that question in plain language.

What Researchers Are Working On Next

The study's authors are candid that their confidence in most of these findings is low to moderate, not high, largely because the trials involved were relatively small and, in several cases, at real risk of bias. They are calling for large, well-designed studies — enrolling many more babies across many more hospitals and countries — to nail down safe treatment lengths with more certainty, especially for suspected-but-unconfirmed infection, where the current signal argues for caution rather than for shortening, and for the two conditions (infected brain-fluid shunts and serious yeast bloodstream infections) where essentially no research on duration exists yet at all. Similar large trials in adults, including one recently testing seven versus fourteen days of antibiotics for bloodstream infections across 74 hospitals in Canada, Australia, New Zealand, Saudi Arabia, Israel, Switzerland, and the United States, suggest the broader medical field is moving in the same direction — treating for exactly as long as necessary, and not a day longer than the evidence supports.[12]

References

  1. Dutta S, Kabra NS, Saini SS, Anne RP, Kadam S, Rameshbabu M, Khurana S, Kiran S. Shorter or biomarker-guided antibiotic durations for common serious neonatal infections: a collection of non-inferiority meta-analyses. eClinicalMedicine. 2025;89:103543. doi:10.1016/j.eclinm.2025.103543 ↩
  2. Lawn JE, Blencowe H, Oza S, et al. Every Newborn: progress, priorities, and potential beyond survival. Lancet. 2014;384(9938):189–205. doi:10.1016/S0140-6736(14)60496-760496-7) ↩
  3. Li G, Bielicki JA, Ahmed ASMNU, et al. Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child. 2020;105(1):26–31. doi:10.1136/archdischild-2019-316816 ↩
  4. Vaughn VM, Flanders SA, Snyder A, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study. Ann Intern Med. 2019;171(3):153–163. doi:10.7326/M18-3640 ↩
  5. Cantey JB, Wozniak PS, Pruszynski JE, Sánchez PJ. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study. Lancet Infect Dis. 2016;16(10):1178–1184. doi:10.1016/S1473-3099(16)30205-530205-5) ↩
  6. Dutta S, Nangia S, Jajoo M, et al. Seven-day versus 14-day antibiotic course for culture-proven neonatal sepsis: a multicentre randomised non-inferiority trial in a low and middle-income country. Arch Dis Child Fetal Neonatal Ed. 2025;110(6):586–594. doi:10.1136/archdischild-2024-328232 ↩
  7. Fursule A, Thakur A, Garg P, Kler N. Duration of antibiotic therapy in neonatal Gram-negative bacterial sepsis—10 days versus 14 days: a randomized controlled trial. Pediatr Infect Dis J. 2022;41(2):156–160. doi:10.1097/INF.0000000000003314 ↩
  8. Islam K, Khatun N, Das K, Paul S, Ghosh T, Nayek K. Ten- vs. 14-day antibiotic therapy for culture-positive neonatal sepsis. J Trop Pediatr. 2023;69(6):fmad036. doi:10.1093/tropej/fmad036 ↩
  9. Stocker M, van Herk W, El Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet. 2017;390(10097):871–881. doi:10.1016/S0140-6736(17)31444-731444-7) ↩
  10. Mathur NB, Kharod P, Kumar S. Evaluation of duration of antibiotic therapy in neonatal bacterial meningitis: a randomized controlled trial. J Trop Pediatr. 2015;61(2):119–125. doi:10.1093/tropej/fmv002 ↩
  11. Mathias S, North K, Santana A, et al. Efficacy of antibiotic regimens for meningitis in young infants aged 0–59 days: a systematic review. Pediatrics. 2024;154(Suppl 1):e2024066588H. doi:10.1542/peds.2024-066588H ↩
  12. The BALANCE Investigators (Daneman N, Rishu A, Pinto R, et al). Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. N Engl J Med. 2025;392(11):1065–1078. doi:10.1056/NEJMoa2404991 ↩